Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases

Clinical Therapeutics

Volumn 26, Issue 11, 2004, Pages 1800-1807

  Moczygemba, Leticia R ^a   Frei, Christopher R ^a,b   Burgess, David S ^a,b,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Univ Texas Hlth Sci Centerat S   (United States)

Author keywords

carbapenems; ESBLs; fluoroquinolones; pharmacodynamics

Indexed keywords

BETA LACTAMASE; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; GRAM NEGATIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; HUMANS; IMIPENEM; KLEBSIELLA PNEUMONIAE; LACTAMS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; OFLOXACIN; THIENAMYCINS;

EID: 11844260120     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.11.009     Document Type: Article

References (38)

1. Wong-Beringer A., Hindler J., and Loeloff M. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime Clin Infect Dis. 34 2002 135 146
2. Nathisuwan S., Burgess D.S., and Lewis J.S. II Extended-spectrum beta-lactamases: Epidemiology, detection, and treatment Pharmacotherapy 21 2001 920 928
3. Jones R.N., Biedenbach D.J., and Gales A.C. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. andESBL-producing Klebsiella spp.: Report from the SENTRY Antimicrobial Surveillance Program (USA, 1997-2000) Int J Antimicrob Agents 21 2003 1 7
4. National Committee for Clinical Laboratory Standards Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically Approved Standard-Sixth Edition 2003 NCCLS Wayne, Pa
5. Bell J.M., Tumidge J.D., and Gales A.C. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: Regional resultsfrom SENTRY Antimicrobial Surveillance Program (1998-1999) Diagn Microbial Infect Dis. 42 2002 193 198
6. Bradford P.A. Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat Clin Microbial Rev. 14 2001 933 951
7. Jacoby G.A., and Sutton L. Properties of plasmids responsible for production of extended-spectrum beta-lactamases Antimicrob Agents Chemother 35 1991 164 169
8. Clark N.M., Patterson J., and Lynch J.P. III Antimicrobial resistance among gram-negative organisms in the intensive care unit Curr Opin Crit Care 9 2003 413 423
9. Livermore D.M., Oakton K.J., Carter M.W., and Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases Antimicrob Agents Chemother 45 2001 2831 2837
10. Livermore D.M., Carter M.W., and Bagel S. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia Antimicrob Agents Chemother 45 2001 1860 1867
11. Hoellman D.B., Kelly L.M., and Credito K. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds Antimicrob Agents Chemother 46 2002 220 224
12. Gesser R.M., McCarroll K., Teppler H., and Woods G.L. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: Analysis of pooled clinical trial data J Antimicrob Chemother 51 2003 1253 1260
13. Paterson D.L., Mulazimoglu L., and Casellas J.M. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase produc tion in Klebsiella pneumoniae isolatescausing bacteremia Clin Infect Dis 30 2000 473 478
14. Lautenbach E., Strom B.L., and Bilker W.B. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae Clin Infect Dis 33 2001 1288 1294
15. Drusano G.L. Prevention of resistance: A goal for dose selection for antimicrobial agents Clin Infect Dis 36 Suppl 1 2003 542 550
16. Andes D., and Craig W.A. Animal model pharmacokinetics and pharmacodynamics: A critical review Int J Antimicrob Agents 19 2002 261 268
17. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 10
18. Signs S.A., Tan J.S., Salstrom S.J., and File T.M. Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration Antimicrob Agents Chemother 36 1992 1400 1403
19. Dreetz M., Hamacher J., and Eller J. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin Antimicrob Agents Chemother 40 1996 105 109
20. Majumdar A.K., Musson D.G., and Birk K.L. Pharmacokinetics of ertapenem in healthy young volunteers Antmicrob Agents Chemother 46 2002 3506 3511
21. Chien S.C., Rogge M.C., and Gisclon L.G. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses Antimicrob Agents Chemother 41 1997 2256 2260
22. Chow A.T., Fowler C., and Williams R.R. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers Antimicrob Agents Chemother 45 2001 2122 2125
23. Nakashima M., Uematsu T., and Kosuge K. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans Antimicrob Agents Chemother 39 1995 2635 2640
24. Lettieri J.T., Rogge M.C., and Kaiser L. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses Antimicrob Agents Chemother 36 1992 993 996
25. Levaquin 2004 Ortho-McNeil Pharmaceutical, Inc Raritan, NJ
26. Tequin 2004 Bristol-Myers Squibb Company Princeton, NJ
27. Cipro 2004 Bayer Pharmaceutical Company West Haven, Conn
28. Merrem 2004 AstraZeneca Pharmaceuticals Wilmington, Del
29. Primaxin 2004 Merck & Co, Inc Whitehouse Station, NJ
30. Invanz 2004 Merck & Co, Inc Whitehouse Station, NJ
31. Ambrose P.G., and Grasela D.M. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: Fluoroquinolone pharmacodynamics against Streptococcuspneumoniae Diagn Microbial Infect Dis 38 2000 151 157
32. Rhomberg P.R., Jones R.N. MYSTIC Program (USA) Study Group Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: Report from the MYSTIC Program (2002) in North America Diagn Microbiol Infect Dis 47 2003 365 372
33. Schmitz F.J., Verhoef J., Fluit A.C. SENTRY Participants Group Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY Surveillance Programme Int J Antimicrob Agents 12 1999 311 317
34. Jones R.N., Pfaller M.A. MYSTIC Study Group (Europe) Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe Clin Microbiol Infect 9 2003 708 712
35. Kohler J., Dorso K.L., and Young K. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates Antimicrob Agents Chemother 43 1999 1170 1176
36. Wexler H.M. In vitro activity of ertapenem: Review of recent studies Antimicrob Chemother 53 Suppl 2 2004 ii11 ii21
37. Nix D.E., Majumdar A.K., and DiNubile M.J. Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians J Antimicrob Chemother 53 Suppl 2 2004 ii23 ii28
38. Tegeder I., Schmidtko A., and Brautigam L. Tissue distribution of imipenem in critically ill patients Clin Pharmacol Ther. 71 2002 325 333